Understanding gene expression in prostate cancer to identify aggressive forms
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancer
This study is looking at how certain genes in the supportive tissue of the prostate can help doctors tell the difference between aggressive and less aggressive prostate cancer, so they can better decide who needs treatment right away and who can safely wait and watch.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10818538 on NIH RePORTER |
What this research studies
This research investigates how gene expression in the prostate's supportive tissue, known as the stroma, can help distinguish between aggressive and non-aggressive forms of prostate cancer. By analyzing tissue samples from patients, the study aims to identify molecular biomarkers that can predict which patients may require immediate treatment versus those who can safely opt for active surveillance. The approach includes advanced techniques like laser-capture microdissection to isolate specific cell types and assess their gene expression patterns. This could lead to more personalized treatment strategies for prostate cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who are at varying risk levels for disease progression.
Not a fit: Patients with non-cancerous prostate conditions or those who have already undergone extensive treatment for prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools that help patients avoid unnecessary treatments and focus on more effective management of their prostate cancer.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for prostate cancer aggressiveness, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Birmann, Brenda M — Brigham and Women's Hospital
- Study coordinator: Birmann, Brenda M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.